Highland Capital Management LLC Sells 890 Shares of Danaher Co. (NYSE:DHR)

Highland Capital Management LLC trimmed its stake in shares of Danaher Co. (NYSE:DHR) by 2.4% during the third quarter, HoldingsChannel.com reports. The firm owned 35,448 shares of the conglomerate’s stock after selling 890 shares during the quarter. Highland Capital Management LLC’s holdings in Danaher were worth $9,855,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Trueblood Wealth Management LLC lifted its holdings in shares of Danaher by 2.5% in the third quarter. Trueblood Wealth Management LLC now owns 3,382 shares of the conglomerate’s stock worth $940,000 after buying an additional 84 shares in the last quarter. Canal Capital Management LLC boosted its holdings in Danaher by 1.8% in the 3rd quarter. Canal Capital Management LLC now owns 15,006 shares of the conglomerate’s stock valued at $4,172,000 after purchasing an additional 265 shares during the period. Mount Yale Investment Advisors LLC grew its position in shares of Danaher by 22.3% during the 3rd quarter. Mount Yale Investment Advisors LLC now owns 3,231 shares of the conglomerate’s stock valued at $898,000 after purchasing an additional 590 shares in the last quarter. Eagle Ridge Investment Management purchased a new stake in shares of Danaher in the third quarter worth $223,000. Finally, Dakota Wealth Management boosted its stake in Danaher by 1.0% during the third quarter. Dakota Wealth Management now owns 8,161 shares of the conglomerate’s stock valued at $2,269,000 after buying an additional 82 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.0 %

Shares of Danaher stock opened at $245.41 on Friday. The company’s 50 day moving average price is $269.52 and its 200-day moving average price is $260.35. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $181.77 billion, a price-to-earnings ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.02 earnings per share. Equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. TD Cowen raised their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday. KeyCorp lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. Raymond James cut their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday. Stifel Nicolaus increased their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday. Finally, Robert W. Baird dropped their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is currently owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.